Optimizing COPD Care: Individualizing Therapy


CME Activity References


Slide 3

  1. Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chron Obstruct Pulmon Dis. 2012;7:1-9.

  2. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

  3. Beeh KM, Beier J. The short, the long and the “ultra-long”: why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv Ther. Mar 2010;27(3):150-159.


Slide 4

Image: Figure adapted from https://wipediseases.org/dev3/inhalers/


  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf


Slide 5

Image: Adapted from the WipeDiseases Foundation figure at https://wipediseases.org: from the Global Strategy for Diagnosis, Management, and Prevention of COPD 2017, Global Initiative for Chronic Obstructive Lung Disease (GOLD), www.goldcopd.org.


  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf


Slide 6

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

  2. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med. Mar 2013;1(1):43-50.


Slide 7

  1. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis. Dec 1978;118(6 Pt 2):1-120.

  2. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. Jul 1999;54(7):581-586.

  3. Sundh J, Janson C, Lisspers K, Stallberg B, Montgomery S. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J. Sep 2012;21(3):295-301.

  4. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. May 2002;121(5):1434-1440.


Slide 9

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf


Slide 11

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf


Slide 13

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

  2. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-94.


Slide 14

Image: Adapted from the WipeDiseases Foundation figure at https://wipediseases.org: from the Global Strategy for Diagnosis, Management, and Prevention of COPD 2017, Global Initiative for Chronic Obstructive Lung Disease (GOLD), www.goldcopd.org.


  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

  2. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. Mar 24 2011;364(12):1093-1103.Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. Sep 2013;1(7):524-533.


Slide 16

  1. Sulaiman I, Cushen B, Greene G, et al. Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. May 15 2017;195(10):1333-1343.

  2. Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med. Feb 2011;105(2):259-265.


Slide 17

  1. Sulaiman I, Cushen B, Greene G, et al. Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. May 15 2017;195(10):1333-1343.

  2. Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med. Feb 2011;105(2):259-265.

  3. Borrelli B, Riekert KA, Weinstein A, Rathier L. Brief motivational interviewing as a clinical strategy to promote asthma medication adherence. J Allergy Clin Immunol. Nov 2007;120(5):1023-1030.


Slide 19

  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2018 Report. Available at: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

  2. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938.

  3. Sulaiman I, Cushen B, Greene G, et al. Objective Assessment of Adherence to Inhalers by Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. May 15 2017;195(10):1333-1343.

  4. Nikander K. Challenges and opportunities in respiratory drug delivery devices. Expert Opin Drug Deliv. 2010;7(11):1235–1238.

  5. Sriram KB, Percival M. Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients. Chron Respir Dis. Feb 2016;13(1):13-22.


Slide 20

  1. Lavorini F, Fontana GA, Usmani OS. New inhaler devices - the good, the bad and the ugly. Respiration. 2014;88:3–15.

  2. Haughney J, Price D, Barnes N, Virchow J, Roche N, Chrystyn H. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010;3:125–131.

  3. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101:2395–2401.

  4. Lavorini F, Magnan A, Christophe Dubus J, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593–604.

  5. Lavorini F, Usmani OS. Correct inhalation technique is critical in achieving good asthma control. Prim Care Respir J. 2013;22:385–386.

  6. Price D, Marshall J, Turner R. Inhaler use in five european countries: analysis of sales data from Q4 2005 to Q4 2011. Value Health. 2012;15:A-PMD92.

  7. Price D, Roche N, Christian Virchow J, Burden A, Ali M, Chisholm A, Lee AJ, Hillyer EV, von Ziegenweidt J. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med. 2011;105:1457–1466.

ABOUT FIGURE 1
LEGAL
HOW  FIGURE 1 WORKS
PRESS